CHMP Scientific Opinions and European Commission Marketing Authorisation Decisions

Introduction

One of the most important distinctions in the European Union centralised marketing authorisation system is the distinction between the scientific opinion of the Committee for Medicinal Products for Human Use (CHMP) and the marketing authorisation decision of the European Commission.

These two steps are closely connected, but they are not the same regulatory act and they should not be described as though they were interchangeable.

The CHMP is the European Medicines Agency's scientific committee responsible for preparing opinions on questions concerning human medicines within its remit. In the centralised marketing authorisation procedure, the CHMP evaluates the application and adopts a scientific opinion on whether the medicine should receive a Union marketing authorisation and under what conditions.

The European Commission subsequently adopts the legally operative Union decision within the framework established by EU pharmaceutical legislation.

A simplified representation is:

Applicant
   |
   v
EMA / CHMP assessment
   |
   v
CHMP scientific opinion
   |
   v
European Commission decision-making process
   |
   v
Commission Implementing Decision
   |
   v
Union marketing authorisation

This distinction matters in regulatory writing, regulatory intelligence, pharmacovigilance and inspection readiness. Saying that "EMA approved the product" may be understandable in ordinary conversation, but it obscures the respective roles of the scientific committee, the Agency and the European Commission.

1. Three Concepts That Should Not Be Confused

A regulatory professional should distinguish at least three related concepts:

1. Scientific assessment — the evaluation of the evidence supporting the application.
2. CHMP opinion — the scientific committee's formal opinion resulting from that assessment.
3. European Commission decision — the legally operative Union decision concerning the marketing authorisation.

The European Medicines Agency supports the scientific and procedural work, but the centralised marketing authorisation is granted through the European Commission's decision under the applicable legal framework.

This distinction is particularly important when interpreting regulatory dates. The date on which CHMP adopts an opinion is not necessarily the same as the date on which the marketing authorisation legally takes effect.

2. What the CHMP Does

The CHMP is a scientific committee within the EMA regulatory system.

In the centralised procedure, it considers the scientific evidence relating to the medicinal product. The assessment covers the quality, safety and efficacy of the medicine and the overall benefit-risk balance.

The scientific assessment is performed through the established EMA assessment process, including the work of rapporteurs and the committee's consideration of the resulting assessment and applicant responses.

The CHMP's role is therefore fundamentally scientific and advisory within the Union decision-making architecture.

It does not itself function as the European Commission.

3. What a CHMP Opinion Represents

A CHMP opinion is the formal scientific position adopted by the committee following its assessment.

For a positive centralised marketing authorisation application, the opinion supports the granting of a marketing authorisation and forms an important part of the subsequent Commission decision-making process.

The opinion can also contain conditions or conclusions that determine the scientific basis for the proposed authorisation, including the applicable product information and, where relevant, risk-management requirements.

The opinion should therefore be read as a substantive scientific regulatory document rather than as an informal recommendation.

At the same time, it should not be described as the final Union marketing authorisation decision.

4. What the European Commission Does

The European Commission is responsible for adopting the legally operative decision in the centralised procedure under the applicable EU legal framework.

The Commission's decision follows the scientific assessment and CHMP opinion but has a different legal character.

The distinction can be summarised as:

This table is intentionally simplified. The Commission decision-making process involves the applicable institutional and legal steps and should not be reduced to a purely administrative signature exercise.

5. Why the Distinction Matters

The distinction becomes important whenever a regulatory professional needs to determine the legal status of a product at a particular point in time.

For example, a CHMP opinion may have been adopted while the Commission decision is still pending.

In that situation, it is inaccurate to treat the product as though the final Commission marketing authorisation decision had already occurred merely because CHMP has adopted a positive opinion.

Similarly, when reconstructing the regulatory history of an authorised medicine, the CHMP opinion and Commission decision should be retained as distinct records.

6. The Centralised Procedure in Context

The centralised procedure is a coordinated Union procedure, but it contains several distinct institutional steps.

The broad sequence is:

Marketing authorisation application
             |
             v
        EMA validation
             |
             v
      Scientific assessment
             |
             v
            CHMP
             |
             v
     CHMP scientific opinion
             |
             v
 European Commission process
             |
             v
 Commission Implementing Decision
             |
             v
 Union marketing authorisation

The precise procedural timetable and legal steps depend on the application and the applicable legislation. The diagram is intended to show institutional responsibility rather than every procedural milestone.

7. The Assessment Behind the Opinion

A CHMP opinion is the endpoint of substantial scientific assessment.

The assessment considers the evidence submitted by the applicant and the questions raised during evaluation.

The regulatory record may therefore contain multiple layers of scientific reasoning, including:

• the applicant's original dossier;
• assessment reports;
• questions and requests for clarification;
• applicant responses;
• expert and committee discussions;
• benefit-risk considerations;
• and the final CHMP opinion.

The opinion should be understood in that context. It is not a replacement for the underlying assessment record.

8. Rapporteurs and the CHMP

The CHMP scientific assessment involves rapporteurs who lead important parts of the evaluation and present the assessment to the committee.

The rapporteur's assessment is not equivalent to the CHMP's final opinion.

The committee considers the scientific evidence and the assessment presented to it before adopting its collective position.

This distinction is useful when reading regulatory documents because a rapporteur assessment, an assessment report and a CHMP opinion can have different procedural status even though they address the same medicinal product.

9. The Opinion Is a Collective Scientific Position

The CHMP opinion should be understood as the committee's collective scientific position following the applicable evaluation process.

This does not mean that every individual scientific question is necessarily free from uncertainty. Regulatory decisions frequently involve uncertainty, especially where evidence is incomplete or the available data are limited.

The important point is that the committee has reached a formal scientific conclusion based on the evidence and the applicable regulatory framework.

10. Positive and Negative Opinions

The centralised procedure can result in different scientific outcomes.

A positive opinion supports the granting of the marketing authorisation, subject to the subsequent legal process.

A negative opinion indicates that the scientific committee does not support the granting of the requested authorisation on the basis of the application as assessed.

The regulatory consequences depend on the applicable legislation and procedural circumstances.

The important principle is that the CHMP opinion is a scientific regulatory conclusion, while the Commission decision is the legally operative Union decision.

11. Product Information and the CHMP Opinion

The scientific opinion is closely connected with the product information that forms part of the proposed authorisation.

This can include:

• the Summary of Product Characteristics;
• the Package Leaflet;
• labelling;
• and other applicable annexes.

The scientific assessment determines the basis for the wording and conditions associated with the medicine.

Consequently, product-information changes should not automatically be treated as editorial changes. A change may represent the implementation of a substantive scientific conclusion concerning efficacy, safety, contraindications, warnings or other regulatory matters.

12. Risk Management

The centralised assessment may also establish or modify risk-management requirements.

Where additional risk-minimisation measures, additional pharmacovigilance activities or other risk-management commitments are required, these form part of the regulatory framework surrounding the authorisation.

The pharmacovigilance organisation should therefore understand the relationship between:

Scientific assessment
       ↓
CHMP opinion
       ↓
Commission decision
       ↓
Authorised product information
       ↓
Risk-management implementation

This chain is important for QPPV oversight because the final authorisation determines the regulatory framework within which the pharmacovigilance system operates.

13. Why "EMA Approved" Is Usually Imprecise

The expression "EMA approved" is common outside specialist regulatory settings.

For technical regulatory writing, it is preferable to specify the actual institutional event.

For example:

• CHMP adopted a positive opinion on [date].
• The European Commission adopted the marketing authorisation decision on [date].
• The medicinal product received a Union marketing authorisation following the Commission decision.

This wording provides substantially better regulatory traceability.

It also avoids attributing the Commission's legal decision to the EMA when describing the institutional roles.

14. The Regulatory Record Should Preserve Both Events

A mature regulatory information system should retain at least:

• the CHMP opinion date;
• the Commission decision date;
• the relevant decision number or identifier;
• the authorised indication;
• the authorised product information;
• applicable conditions of the marketing authorisation;
• and subsequent variations or regulatory decisions.

The distinction becomes particularly useful during regulatory intelligence, due diligence, transfers of responsibility and pharmacovigilance inspections.

The next chunk will examine what happens between the CHMP opinion and the Commission decision and how the final legal authorisation should be interpreted.

15. What Happens Between the CHMP Opinion and the Commission Decision?

The adoption of a CHMP opinion does not mean that the centralised procedure has already produced the final Commission marketing authorisation decision.

The CHMP opinion enters the next stage of the Union decision-making process. The European Commission considers the scientific opinion within the applicable legal and institutional framework before adopting the legally operative decision.

For regulatory tracking, the two dates should therefore be recorded separately:

CHMP opinion date
       ↓
Commission decision process
       ↓
Commission decision date
       ↓
Marketing authorisation

The interval between these events should not be treated as an administrative gap in the regulatory history. It is part of the formal transition from scientific assessment to legal decision.

16. The Commission Does Not Re-run the CHMP Scientific Assessment

The distinction between CHMP and Commission should not be interpreted as meaning that the Commission independently repeats the complete scientific evaluation.

The CHMP provides the specialist scientific assessment and opinion within the EMA system. The Commission's role is to adopt the Union decision under the applicable legal framework, taking account of the scientific opinion and the relevant institutional process.

This division allows scientific expertise and legal decision-making to operate as distinct but connected functions.

17. The Opinion Forms the Scientific Basis of the Decision

For a positive centralised procedure, the CHMP opinion provides the scientific foundation for the marketing authorisation decision.

The final decision should therefore be read together with the CHMP scientific record when a detailed understanding of the regulatory reasoning is required.

For example, if a product has important restrictions, warnings or conditions, the CHMP assessment explains the scientific reasoning that led to those conclusions, while the Commission decision provides the legally operative authorisation.

18. What the Commission Decision Means Legally

The Commission decision is the legally operative act granting or otherwise determining the Union marketing authorisation under the applicable legislation.

This is why the Commission decision is particularly important for regulatory status questions.

A regulatory professional asking "Is this medicine authorised?" should establish the relevant Commission decision and its current status rather than relying only on a historical CHMP opinion.

The decision should also be considered together with subsequent variations, extensions, renewals where applicable, suspensions, withdrawals or other regulatory actions.

19. The Marketing Authorisation and Its Annexes

The centralised marketing authorisation is accompanied by the applicable annexes and product information.

Depending on the regulatory context, the documentation includes the information necessary to define the authorised medicine and the conditions under which it may be marketed.

The regulatory team should therefore avoid treating the Commission decision as a document that can be read independently of its annexes.

For pharmacovigilance purposes, the authorised product information is particularly important because it defines the regulatory baseline against which safety information and risk-management activities are interpreted.

20. Conditions of the Marketing Authorisation

A marketing authorisation may include specific conditions or obligations.

These may be associated with pharmacovigilance, risk management, post-authorisation studies or other regulatory requirements under the applicable framework.

The organisation should maintain a controlled record of such obligations and identify the function responsible for implementation and oversight.

For the QPPV, the important point is that the pharmacovigilance system must operate consistently with the obligations established by the legally operative authorisation and subsequent regulatory decisions.

21. Exceptional Situations and Conditional Authorisations

Not every centralised marketing authorisation has exactly the same regulatory characteristics.

Certain authorisations can be subject to specific conditions or enhanced obligations under EU pharmaceutical legislation, including conditional marketing authorisation or authorisation in exceptional circumstances where applicable.

The presence of such conditions can materially affect the regulatory and pharmacovigilance framework.

A regulatory professional should therefore identify the specific type and conditions of the authorisation rather than assuming that every positive CHMP opinion produces an unrestricted standard marketing authorisation.

22. How to Read the Regulatory Documents Together

For a complete regulatory understanding, a useful reading sequence is:

1. CHMP opinion — identify the scientific conclusion.
2. Assessment report — understand the scientific reasoning and major issues.
3. Commission decision — establish the legally operative outcome.
4. Annexes and product information — determine the authorised terms and conditions.
5. Subsequent Commission decisions and variations — establish the current regulatory status.

This sequence prevents two common errors: treating the scientific opinion as the legal authorisation and treating the legal decision as though it contains all of the underlying scientific reasoning.

23. The Difference Between Scientific and Legal Wording

A CHMP opinion may express scientific conclusions such as a favourable benefit-risk balance under specified conditions.

The Commission decision expresses the legal outcome under the applicable Union framework.

These documents can therefore use different terminology even when they concern the same regulatory conclusion.

Regulatory writing should preserve the distinction rather than attempting to make the documents appear interchangeable.

24. What Happens When the CHMP Opinion Is Negative?

A negative CHMP opinion has a different regulatory pathway from a positive opinion.

The applicant has the procedural rights provided by the applicable legislation, including the possibility of requesting re-examination where the relevant provisions apply.

The regulatory status should therefore not be described simply as "EMA rejected the medicine" without specifying the procedural stage and the institution involved.

A negative CHMP opinion is a scientific committee opinion. The subsequent legal consequences depend on the applicable Union procedure and the resulting decision-making process.

25. Re-examination of a CHMP Opinion

Where the applicable legislation provides a right of re-examination, the applicant can request that the CHMP reconsider its opinion on the grounds permitted by the relevant framework.

This is another reason why the date and status of a CHMP opinion should be recorded carefully.

The initial opinion may not represent the final scientific position if the applicant has initiated a valid re-examination procedure.

A regulatory database should therefore distinguish between:

• initial CHMP opinion;
• request for re-examination;
• final CHMP opinion following re-examination;
• and subsequent Commission decision.

26. Variations After the Original Commission Decision

The regulatory history does not end with the original marketing authorisation.

Post-authorisation changes can alter the authorised product information, conditions or other aspects of the marketing authorisation.

A regulatory professional should therefore distinguish between the original authorisation decision and the current authorisation status.

This is especially important for pharmacovigilance because the reference safety information and risk-management framework can change over the product lifecycle.

27. Implications for Pharmacovigilance

The CHMP opinion and Commission decision have practical implications for the PV system.

The QPPV and PV organisation should be able to establish:

• what risks were recognised at authorisation;
• what information was included in the authorised product information;
• which risks were important identified or potential risks;
• what missing information was recognised;
• which additional pharmacovigilance activities were required;
• and which risk-minimisation measures were imposed.

The legally operative authorisation and its current product information provide the regulatory baseline. The scientific assessment provides the context needed to understand why that baseline was established.

28. Why Regulatory Dates Matter to PV

A safety team may need to determine what information was authorised at a particular historical point in time.

For example, when reconstructing whether a particular adverse reaction was already described in the reference safety information when an event occurred, the team must use the product information and regulatory decisions applicable at that date.

Using the current product information to interpret a historical case can create a false impression of what was known or authorised at the time.

The regulatory history should therefore preserve effective dates and document versions.

29. Regulatory Intelligence Example

Suppose a product has the following timeline:

10 January 2026   CHMP positive opinion
20 February 2026  Commission decision
15 June 2026      Variation modifies product information

A regulatory intelligence record should not collapse these three events into a single statement such as "approved in January 2026".

A more accurate record is:

• CHMP adopted a positive opinion on 10 January 2026.
• The Commission adopted the marketing authorisation decision on 20 February 2026.
• The authorised product information was subsequently modified through a variation effective from the relevant later date.

This level of precision becomes important when interpreting safety information, regulatory commitments and historical status.

30. Common Errors

Saying "EMA granted the marketing authorisation"

The technically appropriate description is that the European Commission adopted the Union marketing authorisation decision, following the EMA/CHMP scientific process.

Treating the CHMP opinion as the final legal authorisation

A positive opinion is a major scientific milestone but is not itself the Commission marketing authorisation decision.

Ignoring re-examination

For negative opinions or other situations where re-examination applies, the initial opinion may not represent the final scientific position.

Using the current product information for historical analysis

Historical regulatory questions require the product information applicable at the relevant time.

Treating the original authorisation as the current regulatory status

Subsequent variations and regulatory decisions can materially change the authorisation.

Separating pharmacovigilance from the authorisation history

The PV system depends on understanding the authorised safety profile, risk-management measures and subsequent regulatory changes.

31. Practical Regulatory Record

A controlled regulatory record for a centrally authorised medicine should ideally include:

This record allows Regulatory Affairs and Pharmacovigilance to work from the same authoritative regulatory history.

32. Relationship to the Existing Centralised Procedure Article

The article How the EU Centralised Marketing Authorisation Procedure Works explains the overall process.

This article deliberately goes deeper into one specific institutional distinction within that process: the CHMP scientific opinion versus the Commission's legally operative decision.

Similarly, the article What Happens After a PRAC Recommendation: CHMP, CMDh and European Commission addresses the pathway following a PRAC recommendation.

The purpose here is narrower: to explain what each document and institutional step means when interpreting the legal and scientific status of a centrally authorised medicine.

Key Takeaways

1. CHMP and the European Commission perform different functions in the centralised marketing authorisation system.
2. The CHMP adopts a scientific opinion following the scientific assessment.
3. The European Commission adopts the legally operative Union marketing authorisation decision.
4. A positive CHMP opinion and a Commission marketing authorisation decision are separate regulatory events.
5. Regulatory records should preserve both events and their respective dates.
6. The Commission decision should be read together with its applicable annexes and product information.
7. Re-examination can affect the status of a CHMP opinion where the applicable legislation provides for it.
8. Subsequent variations and other decisions determine the current regulatory status.
9. Historical pharmacovigilance assessments require the product information and regulatory status applicable at the relevant time.
10. "EMA approved" is generally too imprecise for specialist regulatory writing.

References

1. European Parliament and Council. Regulation (EC) No 726/2004, as amended. Establishes the Union procedures for the authorisation, supervision and pharmacovigilance of medicinal products for human and veterinary use and defines the role of the European Medicines Agency and the centralised procedure.
2. European Parliament and Council. Directive 2001/83/EC, as amended. Community code relating to medicinal products for human use and the wider legal framework for marketing authorisation and post-authorisation regulation.
3. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Current information concerning the committee's role, scientific assessment and opinions.
4. European Commission. Union Register of medicinal products / Community register of medicinal products for human use. Authoritative information concerning Commission marketing authorisation decisions and the legal status of centrally authorised products.
5. European Medicines Agency. European public assessment reports (EPARs). Scientific and regulatory information supporting centrally authorised medicinal products.
6. European Medicines Agency. Post-authorisation procedural guidance for centrally authorised medicinal products. Current guidance on variations, extensions, renewals and other post-authorisation procedures.

Regulatory Note

This article is an educational explanation of the relationship between CHMP scientific opinions and European Commission marketing authorisation decisions for centrally authorised human medicinal products. It does not constitute legal advice and does not replace the current versions of Regulation (EC) No 726/2004, Directive 2001/83/EC, Commission decisions, EMA procedural guidance or product-specific regulatory documents.

The precise procedural and legal consequences of a CHMP opinion depend on the type of procedure, the applicable legislation and whether re-examination or another regulatory step is pending. For a live regulatory matter, the current legally operative documents and applicable procedural guidance take precedence.

The terms "EMA approval" and "CHMP approval" should be avoided in formal regulatory documentation where they obscure the distinction between scientific assessment, CHMP opinion and the European Commission's legal marketing authorisation decision.